RegeneRx Biopharmaceuticals Inc (RGRX)

[All City Baby]

To summarize, we are in a holding pattern while awaiting the results of ARISE-3 early in 2021. Upon success, we believe RegeneRx will have a number of viable options to pursue including potential monetization of RGN-259, access to operating capital at a higher valuation (less dilution) to pursue other asset development, including partnerships for RGN-352 development, and potential uplisting to the NASDAQ market without unacceptable dilution. While difficult, we and all of our stockholders need to remain patient until we learn the results of ARISE-3 in a matter of weeks.

http://filecache.investorroom.com/mr5ir_regenerx_ir/172/Letter%20to%20Stockholders%2012-21-2020%20%28final%29.pdf